SG11201705636SA - Use of prg4 as an anti-inflammatory agent - Google Patents
Use of prg4 as an anti-inflammatory agentInfo
- Publication number
- SG11201705636SA SG11201705636SA SG11201705636SA SG11201705636SA SG11201705636SA SG 11201705636S A SG11201705636S A SG 11201705636SA SG 11201705636S A SG11201705636S A SG 11201705636SA SG 11201705636S A SG11201705636S A SG 11201705636SA SG 11201705636S A SG11201705636S A SG 11201705636SA
- Authority
- SG
- Singapore
- Prior art keywords
- prg4
- inflammatory agent
- inflammatory
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107799P | 2015-01-26 | 2015-01-26 | |
| US201562273059P | 2015-12-30 | 2015-12-30 | |
| PCT/US2016/014952 WO2016123123A1 (en) | 2015-01-26 | 2016-01-26 | Use of prg4 as an anti-inflammatory agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201705636SA true SG11201705636SA (en) | 2017-08-30 |
Family
ID=55361962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705636SA SG11201705636SA (en) | 2015-01-26 | 2016-01-26 | Use of prg4 as an anti-inflammatory agent |
| SG10201809947UA SG10201809947UA (en) | 2015-01-26 | 2016-01-26 | Use of prg4 as an anti-inflammatory agent |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201809947UA SG10201809947UA (en) | 2015-01-26 | 2016-01-26 | Use of prg4 as an anti-inflammatory agent |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10967048B2 (en) |
| EP (2) | EP3250221B1 (en) |
| JP (2) | JP6758299B2 (en) |
| KR (1) | KR20170123619A (en) |
| CN (2) | CN113908257A (en) |
| AU (2) | AU2016211694B2 (en) |
| BR (1) | BR112017015310A8 (en) |
| CA (1) | CA2972817A1 (en) |
| CL (2) | CL2017001893A1 (en) |
| EA (1) | EA036291B1 (en) |
| ES (1) | ES2808199T3 (en) |
| HK (1) | HK1247834A1 (en) |
| IL (2) | IL253596B (en) |
| MA (1) | MA53108A (en) |
| MX (1) | MX2017009723A (en) |
| PH (1) | PH12017501323A1 (en) |
| RU (1) | RU2017129880A (en) |
| SG (2) | SG11201705636SA (en) |
| TN (1) | TN2017000270A1 (en) |
| WO (1) | WO2016123123A1 (en) |
| ZA (1) | ZA201705378B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9982027B2 (en) | 2013-10-22 | 2018-05-29 | Lubris Llc | Control of rheological properties of mixed hyaluronate/lubricin solutions |
| EP3074022B1 (en) | 2013-11-26 | 2022-03-30 | Lubris LLC | Compositions and methods for inhibiting intercellular interactions |
| SG11201705636SA (en) | 2015-01-26 | 2017-08-30 | Lubris Llc | Use of prg4 as an anti-inflammatory agent |
| US11089832B2 (en) | 2015-05-01 | 2021-08-17 | Gentex Corporation | Helmet impact attenuation article |
| LT3300482T (en) | 2015-05-19 | 2021-10-25 | Lubris Llc | Use of prg4 to improve dynamic visual acuity and higher order aberrations |
| CN106215170A (en) * | 2016-08-23 | 2016-12-14 | 重庆医科大学 | Interleukin Ⅲ 6 α treats in preparation, diagnoses or prevent the purposes in medication for treating pyemia |
| US10806581B2 (en) | 2017-05-23 | 2020-10-20 | Harmony Development Group, Inc. | Tethered implantable device having an apical base plate with a hydraulic intracardiac adjusting mechanism |
| WO2019006152A1 (en) | 2017-06-28 | 2019-01-03 | Harmony Development Group, Inc. | A force transducting inflatable implant system including a dual force annular transduction implant |
| WO2019173385A1 (en) | 2018-03-05 | 2019-09-12 | Harmony Development Group, Inc. | A force transducting implant system for the mitigation of atrioventricular pressure gradient loss and the restoration of healthy ventricular geometry |
| CN108795867A (en) * | 2018-06-05 | 2018-11-13 | 华东理工大学 | The method for shifting external threedimensional model for building colon cancer cell peritonaeum |
| TW202017587A (en) * | 2018-06-21 | 2020-05-16 | 美商路布里斯公司 | Lubricin for use in wound healing |
| CN109125709B (en) * | 2018-08-23 | 2021-10-22 | 成都华创生物技术有限公司 | Application of TRAIL mutant in preparation of medicine for treating acne and preparation |
| CN109620952A (en) * | 2019-01-04 | 2019-04-16 | 北京中台恒基生物技术有限公司 | A kind of tumor vaccine and preparation method thereof |
| WO2020232148A1 (en) * | 2019-05-13 | 2020-11-19 | The Johns Hopkins University | Macrophage diversity in regenerative, fibrotic biomaterial environments |
| WO2020247440A1 (en) * | 2019-06-03 | 2020-12-10 | Lubris Llc | Use of prg4 to treat cancer |
| US20230256052A1 (en) * | 2020-07-07 | 2023-08-17 | University Of Connecticut | Method and composition for reducing or preventing bone resorption |
| IT202000022636A1 (en) * | 2020-09-25 | 2022-03-25 | Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter | “COMBINATION THERAPY OF SORAFENIB AND/OR REGORAFENIB WITH THE RECOMBINANT HUMAN PROTEOGLYCAN-4 PROTEIN FOR THE TREATMENT OF HEPATOCARCINOMA” |
| CN114184792B (en) * | 2021-11-17 | 2024-05-28 | 中国人民解放军总医院第二医学中心 | Coronary heart disease marker IL-29 and application thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6433142B1 (en) | 1989-08-08 | 2002-08-13 | Genetics Institute, Llc | Megakaryocyte stimulating factors |
| US6743774B1 (en) | 1999-04-23 | 2004-06-01 | Rhode Island Hospital | Tribonectins |
| US7001881B1 (en) | 1999-04-23 | 2006-02-21 | Rhode Island Hospital | Tribonectins |
| US6960562B2 (en) | 1999-04-23 | 2005-11-01 | Rhode Island Hospital, A Lifespan Partner | Tribonectin polypeptides and uses thereof |
| US20020006665A1 (en) | 2000-04-05 | 2002-01-17 | D'elia John | Ketogulonigenium endogenous plasmids |
| US7415381B2 (en) | 2003-01-09 | 2008-08-19 | Rhode Island Hospital, A Lifespan Partner | Joint friction sensing |
| WO2005000331A2 (en) | 2003-06-04 | 2005-01-06 | Mucosal Therapeutics, Inc. | Compositions for the treatment and prevention of degenerative joint disorders |
| US7642236B2 (en) * | 2003-08-14 | 2010-01-05 | Wyeth | Recombinant lubricin molecules and uses thereof |
| US20090155200A1 (en) | 2004-04-20 | 2009-06-18 | Jay Gregory D | Methods of promoting cartilage healing or cartilage integration |
| EP1778360A2 (en) * | 2004-07-23 | 2007-05-02 | Mucosal Therapeutics LLC | Compositions and methods for viscosupplementation |
| EP1827478A4 (en) | 2004-12-03 | 2009-08-05 | Mucosal Therapeutics Llc | Methods of treatment for injured or diseased joints |
| US20070111327A1 (en) | 2005-05-05 | 2007-05-17 | Jay Gregory D | Methods of detecting lubricin |
| CN101077887A (en) * | 2006-05-23 | 2007-11-28 | 中国医学科学院血液学研究所 | Human accelerated haematogenous cell proliferated cytokine, preparation method and use thereof |
| UY30776A1 (en) | 2006-12-21 | 2008-07-03 | Medarex Inc | CD44 ANTIBODIES |
| WO2008143816A1 (en) | 2007-05-15 | 2008-11-27 | Mucosal Therapeutics | Compositions and methods for reducing friction between the surface of tendons or other soft tissues |
| US20090068247A1 (en) | 2007-09-12 | 2009-03-12 | Mucosal Therapeutics | Biocompatible devices coated with a tribonectin and methods for their production |
| US20090104148A1 (en) | 2007-09-18 | 2009-04-23 | Jay Gregory D | Treatment and prevention of joint disease |
| US20090191287A1 (en) | 2008-01-29 | 2009-07-30 | Johnson W Dudley | Mitigation of Inflammation-Related Injuries |
| US8506944B2 (en) | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
| PT2285364E (en) | 2008-05-07 | 2015-02-24 | Univ California | Therapeutic replenishment and enrichment of ocular surface lubrication |
| US8980840B2 (en) * | 2009-01-13 | 2015-03-17 | Schepens Eye Research Institute | Therapeutic modulation of vaginal epithelium boundary lubrication |
| US9730865B2 (en) * | 2009-05-22 | 2017-08-15 | Lubris, Llc | Application and uses of PRG4 and therapeutic modulation thereof |
| EP2464375B1 (en) | 2009-08-13 | 2017-06-14 | Lubris LLC | Prg4 treatment for interstitial cystitis |
| US11213566B2 (en) | 2010-01-19 | 2022-01-04 | Lubris Llc | Oral care compositions and methods |
| US20130116186A1 (en) | 2011-10-04 | 2013-05-09 | Rhode Island Hospital, A Lifespan Partner | Lubricin injections to maintain cartilage health |
| EP2948553B1 (en) | 2013-01-25 | 2020-04-01 | Baylor College Of Medicine | A helper-dependent adenoviral gene therapy delivery and expression system |
| US9982027B2 (en) | 2013-10-22 | 2018-05-29 | Lubris Llc | Control of rheological properties of mixed hyaluronate/lubricin solutions |
| EP3074022B1 (en) | 2013-11-26 | 2022-03-30 | Lubris LLC | Compositions and methods for inhibiting intercellular interactions |
| SG11201705636SA (en) | 2015-01-26 | 2017-08-30 | Lubris Llc | Use of prg4 as an anti-inflammatory agent |
| US20180161393A1 (en) | 2015-01-26 | 2018-06-14 | Lubris Llc | Prg4 for treating gout and its symptoms |
| LT3300482T (en) | 2015-05-19 | 2021-10-25 | Lubris Llc | Use of prg4 to improve dynamic visual acuity and higher order aberrations |
| US20170312335A1 (en) | 2015-12-30 | 2017-11-02 | Lubris Llc | Topical use of prg4 for treatment of allergy and symptoms of inflammation |
-
2016
- 2016-01-26 SG SG11201705636SA patent/SG11201705636SA/en unknown
- 2016-01-26 EA EA201791688A patent/EA036291B1/en unknown
- 2016-01-26 WO PCT/US2016/014952 patent/WO2016123123A1/en active Application Filing
- 2016-01-26 JP JP2017535349A patent/JP6758299B2/en active Active
- 2016-01-26 ES ES16704975T patent/ES2808199T3/en active Active
- 2016-01-26 EP EP16704975.8A patent/EP3250221B1/en active Active
- 2016-01-26 AU AU2016211694A patent/AU2016211694B2/en active Active
- 2016-01-26 SG SG10201809947UA patent/SG10201809947UA/en unknown
- 2016-01-26 CN CN202111044599.5A patent/CN113908257A/en active Pending
- 2016-01-26 KR KR1020177023786A patent/KR20170123619A/en not_active Application Discontinuation
- 2016-01-26 MX MX2017009723A patent/MX2017009723A/en unknown
- 2016-01-26 TN TN2017000270A patent/TN2017000270A1/en unknown
- 2016-01-26 MA MA053108A patent/MA53108A/en unknown
- 2016-01-26 RU RU2017129880A patent/RU2017129880A/en not_active Application Discontinuation
- 2016-01-26 BR BR112017015310A patent/BR112017015310A8/en not_active IP Right Cessation
- 2016-01-26 US US15/546,192 patent/US10967048B2/en active Active
- 2016-01-26 CA CA2972817A patent/CA2972817A1/en active Pending
- 2016-01-26 EP EP20170338.6A patent/EP3718559A1/en active Pending
- 2016-01-26 CN CN201680007369.2A patent/CN107847556B/en active Active
-
2017
- 2017-07-20 IL IL253596A patent/IL253596B/en unknown
- 2017-07-20 PH PH12017501323A patent/PH12017501323A1/en unknown
- 2017-07-24 CL CL2017001893A patent/CL2017001893A1/en unknown
- 2017-08-08 ZA ZA201705378A patent/ZA201705378B/en unknown
-
2018
- 2018-06-05 HK HK18107350.9A patent/HK1247834A1/en unknown
- 2018-11-21 CL CL2018003302A patent/CL2018003302A1/en unknown
-
2020
- 2020-08-19 JP JP2020138846A patent/JP7212653B2/en active Active
-
2021
- 2021-03-08 US US17/194,747 patent/US11717557B2/en active Active
- 2021-08-11 IL IL285553A patent/IL285553A/en unknown
-
2022
- 2022-02-08 AU AU2022200812A patent/AU2022200812A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285553A (en) | Use of prg4 as an anti-inflammatory agent | |
| EP3199628A4 (en) | Cytotoxicity-inducing therapeutic agent | |
| SG11201706729SA (en) | Derivatives of sobetirome | |
| HK1232137A1 (en) | Therapeutic compounds and compositions | |
| EP3192518A4 (en) | Anti-inflammatory agent | |
| EP3166593A4 (en) | Topical antiviral compositions and methods of using the same | |
| IL285882A (en) | Therapeutic uses of l-4-chlorokynurenine | |
| GB201514758D0 (en) | Formulation | |
| EP3384921A4 (en) | New use of thiopeptin | |
| GB201709918D0 (en) | Topical formulation | |
| ZA201700518B (en) | Use of active compound compositions | |
| LT3173071T (en) | Maropitant formulation | |
| IL246974B (en) | Topical formulations of heparin | |
| PT3340975T (en) | Formulation for the treatment of acne | |
| EP3338775A4 (en) | Use of butylidenephthalide | |
| GB201521771D0 (en) | Formulation | |
| GB201511255D0 (en) | Formulation | |
| GB201509891D0 (en) | Formulation | |
| EP3093020A4 (en) | Anti-malarial agent | |
| SG10202108899XA (en) | Anti-inflammatory agent | |
| GB201602486D0 (en) | Anti-inflammatory formulation | |
| EP3212202A4 (en) | Use of therapeutic agents | |
| GB201911521D0 (en) | Therapeutic agent | |
| GB201516109D0 (en) | Therapeutic agent | |
| GB201514014D0 (en) | Formulation |